Research

REUTERS by Aharon Begley                                                                    Aug. 22, 2015
NEW YORK --An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak.

Although other experimental treatments appeared to help Ebola patients last year, especially in the United States, those one-time uses cannot prove efficacy against the "Makona" strain, since patients' recovery might be due to other causes. Similarly, drugs, including Mapp Biopharmaceutical's ZMapp, cured monkeys in lab experiments, but in a strain of Ebola different from that responsible for the current outbreak, the worst ever recorded.

"We can't say for certain that an experimental drug that works against one strain will work in another, even if they're almost identical genetically," said Thomas Geisbert of the University of Texas Medical Branch, senior author of the study published in the journal Nature.

REUTERS by Kate Kelland                     April 21, 2015

LONDON, April 21 - Genetic sequence data on two of the deadliest yet most poorly understood viruses are to be made available to researchers worldwide in real time as scientists seek to speed up understanding of Ebola and MERS infections.

The project, led by British scientists with West African and Saudi Arabian collaboration, hopes to encourage laboratories around the world to use the live data -- updated as new cases emerge -- to find new ways to diagnose and treat the killer diseases, and ideally, ultimately, prevent them.

"The collective expertise of the world's infectious disease experts is more powerful than any single lab, and the best way of tapping into this...is to make data freely available as soon as possible," said Jeremy Farrar, director of the Wellcome Trust global health charity which is funding the work.

The gene sequences, already available for MERS cases and soon to come in the case of Ebola, will be posted on the website virological.org for anyone to see, access and use.

Read complete story.

http://af.reuters.com/article/topNews/idAFKBN0NC19W20150421?sp=true

USA TODAY by Liz Szabo                                                                 April 14, 2015
Sierra Leone has begun testing an experimental Ebola vaccine, officials of the Centers for Disease Control and Prevention announced Tuesday.
                                                                                            (Photo: CELLOU BINANI, AFP/Getty Images)

The $25 million study, funded through $5.4 billion in Ebola aid authorized by Congress, will test vaccines on 6,000 "front-line workers," including doctors, nurses, burial workers and others, who are at highest risk of the disease.

But with only a handful of new Ebola cases being reported now in Sierra Leone, it may be difficult to get a clear answer on whether the vaccine actually works, the CDC acknowledges. If there are no new cases of Ebola among vaccinated volunteers, for example, researchers won't know if that's the result of the immunizations or because the outbreak has faded....

INQUIRER.NET  by Kristine Angeli Sabillo                  APRIL 8, 2015

MANILA --As the Ebola outbreak in West Africa winds down, the United Nations is optimistic that a vaccine against the deadly virus will be made available in the next several months.

“Clinical trials have have now been undertaken of candidate vaccines, two of them. They are now at an advanced stage,” Dr. David Nabarro, UN secretary general special envoy on Ebola, told reporters in Manila on Wednesday.

“I believe that we will have a vaccine against Ebola that is available and can be used particularly for doctors and nurses who provide treatment for people with the disease in the coming months,” he added.

According to the World Health Organization, the two vaccine candidates undergoing efficacy trials are ChAd3-ZEBOV, developed by GlaxoSmithKline (GSK), and rVSV-ZEBOV, developed by NewLink Genetics and Merck Vaccines USA. The first is being developed in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID) and the second with the Public Health Agency of Canada.

Read complete story.

http://globalnation.inquirer.net/120463/un-envoy-expect-ebola-vaccine-in-coming-months/